News | June 18, 2026
Bayer seals $300 million Perfuse deal
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
Secures high-stakes glaucoma drug in up to $2.45b bet on eye care pipeline
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
The upgraded Rajajipuram centre now features enhanced retina services and advanced OCT technology
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
